Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
CheckMate218
1 other identifier
expanded_access
N/A
2 countries
66
Brief Summary
The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
66 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2014
CompletedFirst Posted
Study publicly available on registry
July 10, 2014
CompletedFebruary 8, 2017
February 1, 2017
July 8, 2014
February 6, 2017
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Men and women 18 years and older
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Histologically-confirmed unresectable stage III or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system, Including mucosal and ocular melanoma
- Subjects must be anti-CTLA-4 treatment-naive and anti-PD-1 treatment-naive. Subjects may have had other prior systemic treatment for localized or metastatic disease
- Subjects with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 2 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. There must also be no requirement for high doses of systemic corticosteroids that could result in Immunosuppression (\>10 mg/day prednisone equivalent) for at least 2 weeks prior to study drug administration
You may not qualify if:
- Active (symptomatic) and not treated brain metastases or leptomeningeal metastases
- Life expectancy \< 6 weeks
- Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in absence of an external trigger are permitted to enroll
- Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment. Inhaled or topical steroids and adrenal replacement steroid doses \> 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease
- Subjects who received prior therapy with an anti-CTLA-4, anti-PD-1, anti-PD-L1 or anti-PD-L2, anti-CT137 (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or subject is expected to require any other form of systemic antineoplastic therapy while receiving nivolumab
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (66)
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
6501 Truxtun Avenue
Bakersfield, California, 93309, United States
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
100 UCLA Medical Plaza
Los Angeles, California, 90095, United States
514 North Prospect Ave
Redondo Beach, California, 90277, United States
California Pacific Medical Center Research Institute
San Francisco, California, 94115, United States
University of California San Francisco
San Francisco, California, 94115, United States
Angeles Clinic and Research Institute
Santa Monica, California, 90404, United States
1325 East Church Street
Santa Monica, California, 93454, United States
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Rocky Mountain Cancer Centers
Littleton, Colorado, 80120, United States
Smilow Cancer Hospital at Yale University Cancer Center
New Haven, Connecticut, 06519, United States
Georgetown-Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
Memorial Regional Hospital
Hollywood, Florida, 33021, United States
4500 San Pablo Road South
Jacksonville, Florida, 32224, United States
Cancer Specialists of North Florida
Jacksonville, Florida, 32256, United States
UF Health Cancer Center at Orlando Health
Longwood, Florida, 32750, United States
Mount Sinai Medical Center
Miami Beach, Florida, 33140, United States
Florida Hospital Cancer Institute
Orlando, Florida, 32804, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
600 Celebrate Life Parkway
Newnan, Georgia, 30265, United States
Evanston Premier Healthcare Research LLC
Evanston, Illinois, 60201, United States
Oncology Specialists, SC
Niles, Illinois, 60714, United States
Local Institution
Louisville, Kentucky, 40202, United States
Medstar Health Research Institute
Baltimore, Maryland, 21204, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Center For Cancer and Blood Disorders
Bethesda, Maryland, 20817, United States
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49503, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148, United States
Atlantic Health System
Morristown, New Jersey, 07960-1089, United States
NYU Langone Medical Center
New York, New York, 10016, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, 10017, United States
Carolinas Healthcare System
Charlotte, North Carolina, 28204, United States
Tulsa Cancer Institute PLLC
Tulsa, Oklahoma, 74146, United States
Northwest Cancer Specialists PC
Portland, Oregon, 97213, United States
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103, United States
St Luke's Hospital
Bethlehem, Pennsylvania, 18015, United States
Greenville Health System
Easley, South Carolina, 29640, United States
Tennessee Oncology PLLC
Nashville, Tennessee, 37203, United States
Texas Oncology
Austin, Texas, 78731, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Texas Oncology
Midland, Texas, 79701, United States
Texas Oncology
Paris, Texas, 75460, United States
Virginia Cancer Institute
Richmond, Virginia, 23230, United States
Oncology and Hematology Associates of Southwest Virginia, Inc
Roanoke, Virginia, 24014, United States
Shenandoah Oncology Association
Winchester, Virginia, 22601, United States
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
University of Wisconsin
Madison, Wisconsin, 53792, United States
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
Grand River Hospital
Kitchener, Ontario, N2G 1G3, Canada
London Health Sciences Centre
London, Ontario, N6A 4L6, Canada
Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9, Canada
Sunnybrook Health Science Centre
Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
McGill University Health Center
Montreal, Quebec, H4A 3J1, Canada
Chuq Centre Hospitalier Universitaire de Quebec
Québec, G1R 2J6, Canada
Related Publications (1)
Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, Atkins M, Spigel DR, Pavlick A, Monzon J, Kim KB, Ernst S, Khushalani NI, van Dijck W, Lobo M, Hogg D. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 Feb 1;31(1):67-75. doi: 10.1097/CMR.0000000000000708.
PMID: 33234846DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb